India Eyes First Dengue Vaccine Launch by Late Next Year
India may soon authorize its first indigenous dengue vaccine by late next year as Phase 3 clinical evaluation progresses across the country. Indian Council of Medical Research (ICMR) Director General Dr. Rajiv Bahl recently shared this regulatory update during the Dilip Mahalanabis Oration in Kolkata. Consequently, healthcare providers across endemic regions are closely monitoring the timeline for this major public health milestone.
Current Clinical Progress of Indigenous Dengue Vaccine
Currently, researchers are evaluating the candidate across 20 premier research institutes nationwide. The randomized controlled trial involves over 13,000 healthy volunteers who receive either the single-dose vaccine or a placebo in a 2:1 ratio. Therefore, two out of every three participants receive the active formulation. The clinical team has completed nearly one full year of prospective monitoring without major safety flags. Additionally, regional centres like the National Institute of Research in Bacterial Infections (NIRBI) in Kolkata are tracking local cohorts to ensure robust multicentric representation.
DengiAll Profile and Tetravalent Protection
The candidate vaccine, known as DengiAll, represents a significant preventive leap for Indian clinicians. Panacea Biotec developed this live-attenuated tetravalent formulation in close collaboration with ICMR. Significantly, it aims to confer simultaneous immunity against all four circulating dengue serotypes (DENV-1 through DENV-4). Furthermore, its single-dose schedule provides a substantial logistical advantage over international multi-dose regimens, which frequently suffer from poor completion rates in community settings.
Epidemiological Factors Influencing Trial Unblinding
However, trial investigators face unique epidemiological challenges before unblinding the study dataset. Unblinding depends strictly on reaching a predetermined number of confirmed symptomatic dengue cases among trial participants. Because several states reported comparatively lower dengue transmission this season, case accrual has proceeded at a moderate pace. Therefore, investigators anticipate unblinding the trial code toward the end of next year to ensure conclusive statistical efficacy.
Frequently Asked Questions
Q1: What is DengiAll and how is it administered?
DengiAll is India's first indigenously developed tetravalent dengue vaccine. Panacea Biotec formulated the vaccine as a convenient, single-dose injectable shot designed to protect against all four dengue serotypes.
Q2: Why might the Phase 3 trial unblinding take until late next year?
Clinical efficacy trials require a specific threshold of laboratory-confirmed dengue cases among enrolled volunteers. Because transmission rates remained relatively low in several regions this year, investigators need additional time to accrue sufficient endpoints.
References
- India may get own dengue vax by next year end: ICMR DG - ETHealthworld
- Press Release - Initiation of Phase III Clinical Trial of DengiAll by ICMR and Panacea Biotec - Press Information Bureau (PIB), Government of India
- Central Drugs Standard Control Organization (CDSCO) - Phase III Clinical Trial Approval Protocol PAN-ICMR-DengiAll-001
